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Jean-Baptiste Ricco, MD, PhD,b, Chapel Hill, NC; and Poitiers, France
As endovascular abdominal aortic aneurysm repair has become increasingly prominent in our vascular surgery practices,
the discussion regarding long-term durability continues. The initial randomized trials that enrolled patients almost
10 years ago revealed a short-term survival advantage with endovascular abdominal aortic aneurysm repair at the expense
of a higher reintervention rate and loss of that initial survival advantage in the longer term. Continuing and healthy
debate over the practical importance of these ﬁndings has resulted in somewhat differing practice patterns on either side of
the Atlantic. This debate explores the issues surrounding whether younger, good-risk patients with a long life expectancy
should be treated with endovascular repair. (J Vasc Surg 2013;58:1709-16.)PART I: YOUNG AND GOOD-RISK PATIENTS the young patient with good risk factors, which serves as
SHOULD BE TREATED WITH ENDOVASCULAR
REPAIR
Raghuveer Vallabhaneni, MD, and Mark A. Farber,
MD, Chapel Hill, NC
Endovascular repair of infrarenal aortic aneurysms
(EVAR) has signiﬁcantly improved during the past 22 years
since JuanParodi et al1 ﬁrst reported their historic cases.
Several commercially available devices are now approved
for EVAR throughout the world. Use of this technique
for infrarenal abdominal aortic aneurysm (AAA) repair
varies worldwide but has been shown to be up to 80% of
all AAA repairs done in the United States.2,3 Despite its
widespread use in most patients, there are still subgroups
in which the beneﬁts of endovascular repair have not clearly
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Although initially thought to be a rare occurrence, this
is an important controversy, because in the United States,
>5000 patients a year aged between 50 and 64 years
undergo aneurysm repair.4 There are substantial reasons
why young patients with good anatomic characteristics
and low comorbidities are very good candidates for
EVAR, and it should be offered to this subgroup.
PERIOPERATIVE OUTCOMES AND EXPERTISE
Several large randomized controlled trials have
compared EVAR with open surgical repair (OSR). The
Comparison of Endovascular Aneurysm Repair with
Open Repair in Patients with Abdominal Aortic Aneurysm
(EVAR-1),5 Dutch Randomised Endovascular Aneurysm
Management (DREAM),6 and Veterans Affairs Open vs
Endovascular Repair (OVER) trials7 showed lower
30-day mortality in patients undergoing EVAR compared
with OSR. It should be noted that the ﬁrst two studies
began enrollment nearly a decade ago. Since that time,
additional device advances, technique improvement, and
understanding in management of patients has occurred.
The Anévrisme de l’aorte abdominale: Chirurgie vs
Endoprothèse (ACE) trial,8 a prospective trial of low-risk
to medium-risk patients, showed equivocal perioperative
mortality between OSR and EVAR. One signiﬁcant crite-
rion for involvement in the ACE trial was expertise in
both EVAR and OSR. On the basis of several articles,9-11
including the ACE trial, this is generally deﬁned as >30
cases per year. Currently, most vascular specialists outside
of major aortic centers rarely perform this volume of
cases.12 The applicability of these outcomes to low-
volume centers is therefore called into question. Most1709
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a year with aneurysmal disease; therefore, their outcomes
would most likely not be the same as those conducted in
the ACE trial. Thus, the results of the ACE trial are only
valid when comparing outcomes at large aortic centers
where >30 cases per year are performed. This is further
supported by the fact that none of the aforementioned
EVAR trials showed a statistical difference in medium-
term to long-term all-cause mortality rates between
EVAR and OSR.7,8,13,14 Thus, it is beneﬁcial and logical
for the practicing physician in a low-volume center to
perform the procedure he or she is most familiar with. In
almost all situations, that would be EVAR based on today’s
training and experience paradigm.12
Medical therapy has also improved outcomes for
EVAR. A recent study showed an increased rate of sac
regression after EVAR in patients who were receiving statin
therapy.15 Other studies have demonstrated a decrease in
all-cause mortality with improved medical management,
including statin therapy, during the past decade.16 This
suggests that some of the outcome and mortality data
from the trials of a decade ago may need to be reinter-
preted if the patients were not all receiving optimal medical
therapy. Other medications, such as doxycycline, have
shown promise in improving outcomes after EVAR as
well.17 As the importance of medical management of aneu-
rysm patients becomes more widely known, durability of
repair in patients with EVAR will likely further improve
and become inconsequential in choosing the best method
of repair.
SECONDARY INTERVENTION RATES
Although the secondary reintervention rate is higher
for EVAR than for OSR, accurate data collection is difﬁ-
cult. Most EVAR interventions are typically managed by
endovascular means. Patients who undergo OSR typically
have more OSR-related complications, such as bowel
obstructions and hernias, which lead to in-patient hospital-
izations.18 In addition, there seems to be a decrease in
secondary interventions from EVAR as experience grows,
advanced devices become available,19 and patient selection
improves. Secondary intervention rates as low as 7.4% have
been achieved.20 This is especially true for open conversion
rates, which have now been reported to be anywhere from
1.6% to 2.6%.21,22 There has also been recent data pub-
lished from the United Kingdom that younger patients
treated with EVAR may have similar rates of secondary
interventions compared with OSR if evaluated after several
years.23
IMPACT OF PATIENT SELECTION
The consideration of a patient’s risk factors includes
physiologic, anatomic, and patient-speciﬁc risk factors.
Patient selection plays a critical role in determiningoutcomes
for EVAR. Implantation of an endoprosthesis into a prea-
neurysmal neck or outside the instructions for use (IFU)
does not convey the same protection against rupture and
long-term outcome compared with the published clinicaltrial results. To be ideal candidates, patients should have
appropriate anatomical criteria for the speciﬁc endograft.
However, a large number of endografts inserted over
the past decade have been outside their deﬁned IFU. Anal-
ysis of a large cohort of these patients has shown an alarm-
ing rate of aneurysm sac enlargement, a high percentage of
type I endoleaks, and an increase in all-cause mortality.24,25
Patients with anatomy within the IFU have lower reinter-
vention rates.24 Because more advanced devices in the
United States have not generally been available until
recently, many patients have been treated outside their
IFU. Although the intraoperative angiogram reveals sufﬁ-
cient aneurysmal exclusion in most instances, it is not until
subsequent follow-up surveillance that many problems are
identiﬁed.26
One of the most important aspects of EVAR is the
crucial importance of follow-up evaluation. Young patients
who are not willing to commit to long-term follow-up are
not good-risk patients for EVAR. Although the risk of
postoperative migration and endoleak is small, it still exists.
Patients who do follow-up on a regular basis should be less
likely to experience ruptures from undiagnosed type I or
type III endoleaks.
PATIENT PREFERENCE
No clinical trial to date has demonstrated a detriment to
the patient when performing EVAR with respect to long-
term mortality. In addition, most studies demonstrate
a distinct advantage of EVAR during the initial years after
repair. It is these two facts that drive most patients in their
decision. Most patients, given the choice, will invariably
choose EVAR over OSR. Several studies have demonstrated
that patients focus on the lower perioperative morbidity and
mortality and the shorter hospital stay with EVAR, even
weighing the risk of higher future secondary interven-
tions.27-29 This also holds true for younger patients because
they may still be employed and want to return to work as
soon as possible to provide for their families. This increased
patient productivity may help reduce the overall economic
effect of EVAR compared with OSR and should be consid-
ered when comparing these different techniques.
COSTS
Cost-comparative analyses between OSR and EVAR
have been attempted, but determining the economic effect
is difﬁcult unless loss of productivity and other factors are
included in the analysis. Many older studies have stated
that EVAR is less cost-effective than OSR, as determined
from an examination of device and hospital charges.30
However, a recent publication from the OVER trial showed
that EVAR costs less in the perioperative period than OSR.7
When the initial 2-year postoperative period was examined,
there was no difference in cost. The outcome of this analysis
is also constantly changing because supply and demand, as
well as hospital costs, change depending on the economic
situation.7 Additional costs are incurred during the follow-
up period because axial imaging studies are used to assess
the effectiveness of EVAR.
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raphy (CT) scans may also increase the risk of induced
malignancy; however, most patients with aneurysmal
disease, even if they are young, would rarely live long
enough to be exposed to this increased risk. As better
knowledge of endograft behaviors and factors that impact
endoleak complications are identiﬁed, alterations in
follow-up have occurred. Many centers have altered the
number of CT scans acquired for surveillance, because
minimum beneﬁt is added if the initial result of the postop-
erative CT scan is found to be normal.26 Institutions have
also begun using a combination of X-ray imaging and color
duplex ultrasound imaging for postoperative evaluation,
further decreasing the costs after implantation.31,32
LIFE EXPECTANCY OF YOUNG PATIENTS
WITH ANEURYSMS
A recently published report from the Nottingham
group looked at midterm survival in young patients treated
with EVAR and OSR.23 When patients treated at their
institution since 1995 were analyzed, nearly 40% of patients
who were treated with OSR or EVAR died #6 years of
their surgery; however, most of these patients did not die
of aneurysmal disease. In patients who were treated with
commercially available endografts, there was a trend
toward improved long-term survival vs earlier custom
made endografts (hazard ratio, 2.9; 95% conﬁdence
interval, 0.9-10; P ¼ .08) and open repair (hazard ratio,
3.1; 95% conﬁdence interval, 0.9-10.3; P ¼ .07); however,
this was not statistically signiﬁcant.23 Patients with aneu-
rysmal aortas may not have the same life expectancy as
patients in the general population, and this may be a risk
factor for early mortality.
CONCLUSIONS
In young, motivated patients with good anatomic and
physiologic risk factors, EVAR is as good as if not better
than OSR when early mortality is factored into the equa-
tion. OSR outcomes are particularly dependent on the
surgeon’s experience, and that has become extremely
limited in recent years. There are potential risks of future
secondary interventions with EVAR; however, most of
these are also repaired endovascularly, and the chance of
needing an open surgical revision is extremely low. The
costs of EVAR and OSR are becoming comparable, espe-
cially when societal effect is considered, as hospital costs
increase, graft costs decline with competition, and alterna-
tive postoperative surveillance occurs. As medical manage-
ment, operator expertise, and endograft technology
improve, the long-term outcomes of endovascular therapy
should also continue to improve.
Young patients with aneurysms may also not have the
same long-term survival as the general population and
may beneﬁt from a procedure with lower perioperative
risk. The current data suggest that in young, good-risk
patients, the long-term mortality in EVAR and OSR are
equivocal. However, there tends to be less perioperative
mortality in EVAR, especially if the center’s OSR volumeis limited. Therefore, only in centers of excellence, should
both OSR and EVAR be offered to all young, good-risk
patients to allow the patients to decide. In almost all cases,
they will choose EVAR. In all low-volume practices, EVAR
should be preferentially offered.REFERENCES
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SHOULD NOT BE TREATED WITH ENDOVAS-
CULAR REPAIR
Fabrice Schneider, MD, PhD, and Jean-Baptiste
Ricco, MD, PhD, Poitiers, France
Surgical repair is indicated for large asymptomatic
abdominal aortic aneurysms (AAAs) in patients with an
acceptable operative risk. After the landmark report by Par-
odi et al,1 early results of randomized controlled trials
(RCT)2-4 have demonstrated lower perioperative mortality
after endovascular aortic aneurysm repair (EVAR) comparedwith open repair (OR). Next to these results, the number of
patients receiving EVAR exceeded those treated by OR.5
However, some years later, the midterm results of these
RCTs have shown equivalent mortality after EVAR or OR,
with a signiﬁcantly higher reintervention rate after EVAR
failing to support evidence favoring its use as ﬁrst-line
therapy, especially in young or ﬁt patients, or both.6-8 The
goal of this debate is to compare early and late outcomes
in patients aged <65 years receiving OR or EVAR.
THE PROBLEM
During the last decade, EVAR has radically changed
the approach for treating AAAs. In the United States,
EVAR rose from 11,171 procedures in 2001 to 21,725
procedures in 2006.5 The same paradigm shift was
observed in France, regardless of the patient’s age, with
777 EVAR procedures in 2006 compared with 372 in
2001.9 Currently in the United States, 60% of AAAs are
repaired by EVAR.10 But the use of EVAR in young
patients calls into question the long-term beneﬁts and
durability of this procedure. To answer these questions,
analyses of the survival rate, the risk of device-related
complications, including radiation exposure by computed
tomography (CT) scan,11 and cost-effectiveness with
regard to devices and reinterventions are essential
(Table I).
THE EVIDENCE
Comparison of EVAR with OR in patients deemed ﬁt
for surgery is available in four RCTs (Table II). The
Comparison of Endovascular Aneurysm Repair with
Open Repair in Patients with Abdominal Aortic Aneurysm
(EVAR-1) trial involved 1252 patients from 1999 to 20048
and demonstrated an initial beneﬁt in aneurysm-related
mortality in favor of EVAR at 6 months. But this beneﬁt
vanished after 4 years, and the risk of aneurysm-related
death, w7%, was equivalent for the two groups at 6 years.
In addition, there were more reinterventions and complica-
tions in the EVAR group. At 8 years, the complication rate
was 52% for EVAR vs 15% for OR (P ¼ .01), and the
Table II. Randomized controlled trials (RCTs) comparing endovascular aneurysm repair (EVAR) with open repair (OR)
for abdominal aortic aneurysms (AAAs)
References Patients, No. Age,a years
Follow-up,
years
Perioperative
mortality Outcomes
EVAR-1, 2005,3 20108 OR: 539 74 6 6.1 6 OR: 6.2% Overall aneurysm-related death:
1.2/100/y with OR vs 1/100/y
with EVAR (P ¼ .73)
EVAR: 543 74.2 6 6.0 EVAR: 2.1% Overall mortality: 7.1/100/y with
OR vs 7.2/100/y with EVAR
(P ¼ .61)
(P ¼ .001) Reintervention rate: 1.7/100/y
with OR vs 5.1/100/year with
EVAR (P < .001)
AAA rupture: 0 after OR vs 25
after EVAR (4.6%)
DREAM, 2005,4 20107 OR: 174 69.6 6 6.8 6.4 OR: 4.6% Overall mortality: 30.1% with OR
vs 31.1% with EVAR (NS)
EVAR: 171 70.7 6 6.6 EVAR: 1.2% AAA-related mortality: 4.49% with
OR vs 1.15% with EVAR
(P < .001)
(P ¼ .01) Reintervention rate: 18.1% after
OR vs 29.6% after EVAR
(P ¼ .003)
OVER, 2009,2 20126 OR: 437 70.5 6 7.8 5.2 OR: 3% (P ¼ .004) Overall mortality: 33.4% after OR
vs 32.9% after EVAR (NS)
EVAR: 444 69.6 6 7.8 EVAR: 0.5% AA-related mortality: 3.7% after
OR vs 2.3% after EVAR (NS)
AAA rupture: 0 after OR vs 6
(1.4%) after EVAR (P ¼ .03)
Reintervention rate: 17.8% after
OR vs 22.1% after EVAR (NS)
ACE, 201112 OR: 149 70 6 7.1 3 OR: 0.6% Overall mortality: 8% after OR vs
11.3% after EVAR (NS)
EVAR: 150 68.9 6 7.7 EVAR: 1.3% AAA-related mortality: 0.6% after
OR vs 4% after EVAR (NS)
(P > .05, NS) AAA rupture: 0 after OR vs 3
(2.0%) after EVAR (NS)
Reintervention rate: 2.7% after OR
vs 16% after EVAR (P < .0001)
ACE, Anévrisme de l’aorte abdominale: Chirurgie vs Endoprothèse; DREAM, Dutch Randomised Endovascular Aneurysm Management; EVAR-1,
Comparison of Endovascular Aneurysm Repair with Open Repair in Patients with Abdominal Aortic Aneurysm; NS, not signiﬁcant; OVER, Veterans Affairs
Open vs Endovascular Repair.
aData for age are presented as mean 6 standard deviation.
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addition, 25 aortic ruptures, with 18 deaths, occurred in
the EVAR group (4%) and none in the OR group. These
late ruptures outweighed the initial beneﬁts of EVAR.
The Dutch Randomised Endovascular Aneurysm
Management (DREAM) trial4,7 demonstrated the same
initial beneﬁts for EVAR, with a lower rate of in-hospital
mortality (1.2% vs 4.6% for OR; P < .05) but with a higher
rate of cardiovascular-related death in the EVAR group at
1 year, which outweighed its initial beneﬁt in survival at
2 years. There were also more reinterventions in the
EVAR group (29.6% for EVAR vs 18.1% for OR; P ¼ .03),
with an increased rate of reinterventions after 4 years in
the EVAR group, 75% being related to stent graft failure.
The Veterans Affairs Open vs Endovascular Repair
(OVER) trial2,6 also showed a signiﬁcant decrease inhospital mortality in favor of EVAR (0.5%) vs OR (3%;
P ¼ .004), which remained signiﬁcant at 3 years. In
contrast to the EVAR-1 and DREAM trials, there was no
difference in the rate of reinterventions between EVAR
and OR during this study. Mortality in this trial was
analyzed according to several risk factors, including age,
and showed an advantage for EVAR in young patients
(aged <70 years) compared with OR even if a higher inci-
dence of cancer in the OR group could explain this differ-
ence and even though six AAA ruptures with three deaths
occurred in the EVAR group.
The results of the Anévrysme de l’aorte abdominale,
Chirurgie vs Endoprothèse (ACE) trial12 comparing OR
(n ¼ 149) with EVAR (n ¼ 150) in low-risk to
moderate-risk patients showed no signiﬁcant difference in
in-hospital mortality between the two groups (0.6%
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terventions was higher in the EVAR group (16% vs 2.7%;
P < .0001), with three ruptures resulting in two deaths
vs no rupture in the OR group. The absence of early
beneﬁt of EVAR in this trial was explained by the low
mortality rate of the OR group.
What have we learned from these studies? These four
RCTs did not investigate the performance of EVAR
among different age groups, and the mean age of the
patients in these RCTs did not match with the deﬁnition
of young patients and call into question the applicability
of their conclusions for young patients. Other studies have
concentrated exclusively on the elderly population.13,14
However, with the development of AAA screening, there
will surely occur an increase of young patients eligible for
AAA repair. In a recent retrospective study of data extracted
from the American College of Surgeons National Surgical
Quality Improvement Program data ﬁles, Gupta et al15
compared the results of EVAR in patients aged $60 years
vs younger patients. This study failed to show any early
beneﬁt in mortality for EVAR (1.1%) vs OR (0.4%; P ¼
.22). However, major complications were signiﬁcantly
higher for OR (18.8%) than for EVAR (9.2%; P ¼ .0004).
This contemporary study demonstrates that 30-day
mortality after ORwas comparable to 30-day mortality after
EVAR in patients aged <60 years.
In association with age, women have been reported to
have a higher risk for complications after AAA repair.16 In
this study involving patients aged <60, female gender was
not associated with 30-day mortality or morbidity on
multivariate regression analysis. A recent study showed
that women with AAAs were signiﬁcantly older than men
and less likely to undergo EVAR as a result of a less favor-
able vascular anatomy.17 These data suggest a limited effect
of female gender on outcome for young patients.
TECHNICAL IMPROVEMENTS OF EVAR
The use of ﬁrst-generation stent grafts and early experi-
ence of EVAR are signiﬁcant factors that have resulted in
some of the complications reported in EVAR-1, DREAM,
and OVER.14 Technical improvements of EVAR securing
the sealing zone more precisely and decreasing stent graft-
related complications call into question the use of these
results nowadays. Two pivotal studies with recent stent
grafts have reported a rate of device-related complications
of <3%, with only one rupture during follow-up.18,19 Less
promising in these studies is the 15% rate of type II endoleak
reported in the Zenith pivotal study19 and the 15% rate of
sac enlargement without visible endoleak in 15% of the
patients in the Excluder Low-Permeability Pivotal Study.20
These recent data still call into question the efﬁcacy of stent
grafts, even with the newest-generation devices.
Moreover, a worrisome recent report by Schanzer et al21
showed an incidence of post-EVAR aneurysmal sac enlarge-
ment of 41% at 5 years despite the use of new-generation
stent grafts. The main reason for this adverse outcome was
partially related to a more liberal indication of EVAR
exceeding the instructions for use. More than the patient’spreference, appropriate anatomic criteria are critical to decide
between OR and EVAR in this young population.
Stent graft outcome in young patients remains
a concern if they live long enough. The main limitation
in recommending EVAR in young patients is the risk of
stent graft-related complications due to their longer life
expectancy. Some authors, citing the results of the Multi-
centre Aneurysm Screening Study (MASS) with 11% of
patients dying #4 years of their aneurysm operation,22
consider that the life expectancy of these young patients
is already poor. Most are likely to die from coronary
disease, cancer, or other cardiovascular causes. A recent
study by Darwood et al23 reported a 42% mortality at
2 years in patients with a 4- to 5-cm AAA. They speculate
that even though young, these patients with AAAs have
a short life expectancy and that a stent graft was all that
was required. Perhaps, the main issue in these young
patients with AAAs is not the choice of EVAR or OR but
rather the prevention of cardiovascular complications with
a better medical management, including statin therapy.
However, there is no level I evidence to support this
hypothesis, and long-term RCTs have shown that the
difference in morbidity between OR and EVAR in the
DREAM and in the EVAR-1 trials was partially explained
by a higher rate of reintervention after EVAR,7,8 even
when accounting for an underestimation of the late compli-
cations after OR.24 These data suggest that young patients
do survive long enough to face stent graft-related compli-
cations, including AAA rupture, which remains three times
more frequent after EVAR than after OR.24
It is also clear that prior EVAR does not confer any
protective effect in the setting of a ruptured AAA.25
The risk of ruptured aneurysm after EVAR underscores
the need for regular monitoring by CT scan, with the risk
of radiation exposure during many years of follow-up.
A CT scan with contrast media at 1, 6, and 12 months,
and annually thereafter, is tantamount to a total effective
radiation dose of 145 to 205 mSv over 5 years, which trans-
lates into a lifetime cancer risk of 1% for a 50-year-old
patient.11 To limit radiation exposure, some authors
recommend a “light” follow-up based on the results of
an early CT scan.26 The most promising solution consists
in the use of contrast-enhanced ultrasound imaging, which
has demonstrated comparable sensitivity and speciﬁcity
with the CT scan in the detection of endoleak after
EVAR.27,28 Up to now, the main limitation to its wide-
spread use remains the experience of the operator.
Finally, cost issues also play an important role when dis-
cussing the use of stent grafts in young patients. EVAR-18
found that the average cost of aneurysm-related procedures
after 8 years of follow-up was higher for EVAR ($23,153)
than for OR ($18,586). This raw analysis could be unfair,
because the costs of some laparotomy-related complica-
tions were not taken into account in the cost-analysis.
However, even in recent series, EVAR continues to cost
more than OR,29 and an updated report from the French
Health Agency (Haute Autorité de santé) designed to eval-
uate the cost-effectiveness of EVAR in France concluded
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 6 Vallabhaneni et al 1715that EVAR was not a viable economic solution, especially
in patients ﬁt for surgery.30
CONCLUSIONS
There is no evidence in the recent literature to support
EVAR as the ﬁrst-line therapy in young patients
aged<60 years.ORremains the best option formost of them.REFERENCES
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